ClinicalTrials.gg
Not yet recruitingNCT06107335Updated Dec 6, 2024

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

A Phase 4 interventional study of Human Albumin (colloid) and Lactated Ringer's Injection (crystalloid) in Pre-Eclampsia, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by The University of Texas Health Science Center, Houston · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Planned enrollment
93rd of 161
62 · median 89
Started
2025
with 12 others
Phase 4
31 of 230
11 open now
Primary completion
2026-12
later than 22 of 77 live
Registered
174th of 230
by date

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 93rd largest by planned enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 31 in phase 4, reaches primary completion later than 22 of the 77 other live ones, and was the 174th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Pre-Eclampsia studies recruiting now, 80 (50%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of albumin versus routine care on hemodynamic response and stability in pre-eclamptic patients during cesarean delivery. The hypothesis is that volume replacement with albumin guided by stroke volume variation (SVV) using a ClearSight-Acumen (CS-A) monitor, before cesarean delivery (CD), improves hemodynamic stability in preeclamptic patients with severe features compared to routine care, under neuraxial anesthesia.

03

Conditions studied

  • Pre-Eclampsia

Browse trials for

Keywords

  • Pre-Eclampsia
  • Albumin
  • Hemodynamic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age greater or equal to 24 weeks
  • Diagnosis of preeclampsia with severe features [Pre-eclampsia is defined as high blood pressure after 20 weeks with or without proteinuria. Pre-eclampsia with severe features is defined as the presence of preeclampsia with any of the following features: severe hypertension (blood pressure ≥160/110 mmHg on two separate occasions); thrombocytopenia ( count \<100,000 per microliter); impaired liver function (elevated liver transaminases to twice the normal concentration or severe persistent right upper quadrant or epigastric pain not responsive to medications); progressive renal insufficiency with a serum creatinine level of >1.1 mg/dl or doubling of the serum creatinine level in the absence of other renal disease; pulmonary edema or unexplained new-onset cerebral symptoms (headache) unresponsive to medications or visual disturbances.]
  • Scheduled Cesarean Delivery
  • Unscheduled Cesarean Delivery with the goal to proceed to the operating room within no less than 30 minutes due to concern for maternal or fetal status that is not immediately life threatening.
  • Requiring Neuraxial Anesthesia (spinal or CSE)

Exclusion criteria

Exclusion Criteria:

  • Patient declines to participate in the study
  • Labor
  • to the use of neuraxial anesthesia (coagulopathy, infection at the insertion site, intracranial mass etc.)
  • Unscheduled Cesarean Delivery with the goal to proceed to the operating room immediately for delivery of the baby due to imminent/unavoidable threat to the life of the mother or fetus.
  • The use of or conversion to General Anesthesia
  • Non-reassuring fetal status including the presence of cardiac or multi-system anomalies, category III tracing etc.
  • Significant maternal cardiopulmonary disease including pulmonary hypertension, ischemic heart disease with systolic dysfunction, pulmonary edema etc.
  • Significant intraoperative events (such as hemorrhage) requiring administration of multiple blood products and ICU admission.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Fluid restriction using crystalloid

    Fluid restriction will be achieved with the crystalloid lactated ringer's injection administered at at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr).

    Drug: Lactated Ringer's Injection (crystalloid)

  • Experimental
    Fluid replacement using colloid as guided by stroke volume variation (SVV)

    Fluid replacement will be achieved with the colloid 5% albumin infusion. Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device.

    Drug: Human Albumin (colloid) · Device: Edwards HemoSphere monitor with ClearSight-Acumen finger cuff

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).

    Also known as: Albutein

  • DrugRinger's LactateStudies of Ringer's LactateRinger's Lactate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.

  • DeviceEdwards HemoSphere monitor with ClearSight-Acumen finger cuff

    Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.

06

What researchers measure

Primary outcomes

  1. Number of participants with fluid responsiveness

    "Fluid responsiveness" (in other words, a "positive response") is defined as a volume-induced correction to stroke volume variation (SVV) values \< 13%. SVV measurements will be made using the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff.

    Time frame: from baseline to thirty minutes after arrival to the Post Anesthesia Care Unit (PACU)

Secondary outcomes

  1. Number of participants with fluid responsiveness stability

    Time frame: from baseline to thirty minutes after arrival to the Post Anesthesia Care Unit (PACU)

  2. Maternal blood pressure (diastolic)

    Time frame: baseline, after infusion of study intervention, at completion of placement of the spinal/CSE anesthesia, at completion of delivery of the baby, at end of procedure when leave operating room, thirty minutes after arrival to PACU

  3. Maternal blood pressure (systolic)

    Time frame: baseline, after infusion of study intervention, at completion of placement of the spinal/CSE anesthesia, at completion of delivery of the baby, at end of procedure when leave operating room, thirty minutes after arrival to PACU

  4. Total amount in milligrams of rescue vasopressor drug given

    Time frame: from start of operation to thirty minutes after arrival to the Post Anesthesia Care Unit (PACU)

  5. Number of adverse events

    Time frame: from start of operation to discharge from the Post Anesthesia Care Unit (PACU)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartEst.
Jul 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06107335
Responsible party
Onyi C Onuoha (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Oct 30, 2023
Start date
Jul 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 6, 2024

Study contacts

Barbara Orlando, MD
Contact
barbara.orlando@uth.tmc.edu
917-496-7490
Onyi Onuoha, MD, MPH
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion